Clinical Trial Update: Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating camrelizumab with nab-paclitaxel and carboplatin in stage IB-IIIA non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Camrelizumab (camrelizumab)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Lung Cancer, Non-small Cell, Artificial Intelligence | Phase 2 | Status: UNKNOWN